Clinical Trials
51 trialsSafety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Shasqi, Inc.
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Eli Lilly and Company
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
ADC Therapeutics S.A.
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Foghorn Therapeutics Inc.
MANTRA
Rain Oncology Inc
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
Noxopharm Limited
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
C4 Therapeutics, Inc.
TTI-621-03
Pfizer
MODULATE
Immodulon Therapeutics Ltd
CAR
Shanghai PerHum Therapeutics Co., Ltd.
CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas
Shanghai PerHum Therapeutics Co., Ltd.
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
Sumitomo Pharma America, Inc.
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
NantCell, Inc.
Camsirubicin + Pegfilgrastim to Determine MTD in ASTS
Monopar Therapeutics
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
Jiangsu HengRui Medicine Co., Ltd.
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Y-mAbs Therapeutics
LODESTAR
pharmaand GmbH
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Eli Lilly and Company
NBE-002 in Patients With Advanced Solid Tumors
NBE-Therapeutics AG
ALpha-T
Hoffmann-La Roche
VITA
Gradalis, Inc.
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Pfizer
REVEAL
Nektar Therapeutics
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
Genentech, Inc.
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
Hoffmann-La Roche
A Safety Study of SGN-CD47M in Patients With Solid Tumors
Seagen Inc.
IMDZ-C232
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
Celgene
Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
Lexent Bio, Inc.
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Merck KGaA, Darmstadt, Germany
MMS-TM
MedInnovation GmbH
Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma
Champions Oncology
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
Pfizer